Get started
Author

Federico Longo-Muñoz

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
2017 · Eric Van Cutsem, Robert J. Mayer, et al. · European Journal of Cancer · 96
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
2017 · Alfredo Carrato, Albert Abad, et al. · European Journal of Cancer · 87
Does Rapid Drug Desensitization to Chemotherapy Affect Survival Outcomes?
2019 · MP Berges-Gimeno, LV Carpio-Escalona, et al. · Journal of Investigational Allergology and Clinical Immunology · 37
PDF
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial
2016 · F. Longo-Muñoz, G. Argiles, et al. · Clinical & Translational Oncology · 33
PDF
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors
2021 · Edouard Auclin, Perrine Vuagnat, et al. · Cancers · 15
PDF
Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
2021 · Pilar García-Alfonso, Andrés Muñoz, et al. · Cancers · 14
PDF
Abstract P3-09-19: Preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer
2020 · Joel Randolph Hecht, Arlene Chan, et al. · Cancer Research · 9
Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis
2025 · Alberto Langtry, Raul Rabadan, et al. · Nature Communications · 4
PDF
A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study
2026 · Jiangchuan He, Sergio Sabroso-Lasa, et al. · Cancer Epidemiology Biomarkers & Prevention
Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis
2026 · Alberto Langtry, Raul Rabadan, et al. · Nature Communications
PDF
Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis (Nature Communications, (2025), 16, 1, (10769), 10.1038/s41467-025-65811-y)
2026 · Raul Rabadan, Lola Alonso, et al. · Newcastle University ePrints (Newcastle Univesity)
Economic Evaluation of Oxaliplatin Hypersensitivity: A Retrospective Cohort Study
2025 · Laura V. Carpio-Escalona, Federico Longo-Muñoz, et al.
PDF
Works count: 12
Citation count: 295
H-index: 7
I10-index: 6
Year
Topic
Type